Curis (CRIS) provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia, or AML, triplet study in a poster presentation at the 67th ASH Annual Meeting. The AML triplet study is evaluating the addition of emavusertib to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on ven-aza but remain MRD-positive, with the goal of enabling patients to achieve uMRD. The company reported initial data showing 4 of 8 patients had achieved uMRD as of July 2, 2025. These data were updated in the poster presented at ASH with 5 of 8 patients achieving uMRD, with no change in safety profile, as of October 12.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS:
- Promising Early Data from Curis’s Emavusertib Study Supports Buy Rating
- Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
- Curis Inc. Earnings Call: Clinical Progress and Financial Gains
- Curis Inc. Advances Cancer Trials with Promising Results
- Curis Completes Sale of Erivedge Business